Ocular Therapeutix reports lower net loss in third quarter

Ocular Therapeutix reported a net loss of $9.6 million, or $0.39 per share, in the third quarter compared with a net loss of $11.5 million, or $0.47 per share, in the third quarter of 2015, according to a company press release.

Total costs and operating expenses were $9.7 million compared with $11.6 million in the third quarter of 2015, while research and development costs decreased from $8.3 million to $5.7 million. The decrease was attributed to lower clinical trial costs.

Revenue totaled $477,000 compared with $429,000 in the third quarter of 2015.